Investor Stock List
Ranked #4,981 of 8,699 institutional investors

Aisling Capital Management LP

New York, NY

$298M
US stock portfolio at live prices · today −$3.9M (−1.30%)
Live prices, last trade 11:14 AM ET
Value at quarter end (Q3 2026)
$299M
Change from Q2 2026
−$172.3M (−36.53%)
Positions
13 · 0 new, 0 sold out
Filed
Nov 12, 2026

Not counted in the ranking: none$4.4M of holdings we could not match to a US listing are included at their reported quarter-end value.

Holdings

Q3 2026 13F, live prices
BBIO 80.2%CMPS 4.72%GLUE 4.56%SNDX 4.00%BCAX 1.66%
StockSharesValue, live% of portfoliovs Q2 2026
BBIO BridgeBio Pharma, Inc.3,089,611$239M80.2%Reduced −33%
CMPS COMPASS Pathways plc1,732,336$14.1M4.72%Added +21%
GLUE Monte Rosa Therapeutics, Inc.1,555,664$13.6M4.56%Unchanged
SNDX Syndax Pharmaceuticals, Inc.1,316,806$11.9M4.00%Unchanged
BCAX Bicara Therapeutics Inc.548,919$4.9M1.66%Reduced −4%
SRRK Scholar Rock Holding Corporation42,031$2.1M0.72%Reduced −45%
EPRX Eupraxia Pharmaceuticals Inc.325,000$1.9M0.65%Unchanged
BBOT BridgeBio Oncology Therapeutics, Inc.1,018,018$1.9M0.63%Unchanged
ACRS Aclaris Therapeutics, Inc.434,455$1.5M0.51%Unchanged
BMEA Biomea Fusion, Inc.2,048,757$1.2M0.41%Unchanged
VTVT vTv Therapeutics Inc.58,775$934K0.31%Added +18%
MRKR Marker Therapeutics, Inc.325,370$397K0.13%Unchanged
OKUR OnKure Therapeutics, Inc.88,607$245K<0.1%Unchanged